136 related articles for article (PubMed ID: 17542352)
1. Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.
van Os S; Relleke M; Piniella PM
Int J Clin Pharmacol Ther; 2007 May; 45(5):293-9. PubMed ID: 17542352
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers.
Cánovas M; Delgadillo J; Torres F; Riba N; Cebrecos J; Pelagio P; Cabré F
Int J Clin Pharmacol Ther; 2009 Feb; 47(2):124-31. PubMed ID: 19203569
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand.
Boonleang J; Pipatrattanaseree W; Tanthana C; Mahatthanatrakul W
Clin Ther; 2010 Sep; 32(10):1842-53. PubMed ID: 21194608
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.
van Schaick EA; Lechat P; Remmerie BM; Ko G; Lasseter KC; Mannaert E
Clin Ther; 2003 Jun; 25(6):1687-99. PubMed ID: 12860492
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers.
Khorana N; Maphanta S; Lohitnavy O; Srichaiya A; Sayasathid J
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):409-14. PubMed ID: 21612749
[TBL] [Abstract][Full Text] [Related]
6. Risperidone: effects of formulations on oral bioavailability.
Gutierrez R; Lee PI; Huang ML; Woestenborghs R
Pharmacotherapy; 1997; 17(3):599-605. PubMed ID: 9165565
[TBL] [Abstract][Full Text] [Related]
7. Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers.
Huang M; Shen-Tu J; Hu X; Chen J; Liu J; Wu L
Clin Ther; 2012 Jun; 34(6):1432-9. PubMed ID: 22595151
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.
Belotto KC; Raposo NR; Ferreira AS; Gattaz WF
Clin Ther; 2010 Nov; 32(12):2106-15. PubMed ID: 21118746
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of two risperidone orodispersible tablet products after single dose administration.
Tassaneeyakul W; Kumar S; Gaysonsiri D; Kaewkamson T; Khuroo A; Tangsucharit P; Phunikhom K; Vannaprasaht S; Kanjanawart S; Rao Thudi N; Jain R; Reyar S; Monif T
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):614-20. PubMed ID: 20860915
[TBL] [Abstract][Full Text] [Related]
10. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
Cho HY; Lee YB
Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
[TBL] [Abstract][Full Text] [Related]
14. A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions.
Elshafeey AH; Elsherbiny MA; Fathallah MM
Clin Ther; 2009 Mar; 31(3):600-8. PubMed ID: 19393850
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study.
Di Girolamo G; Czerniuk P; Bertuola R; Keller GA
Clin Ther; 2010 Jan; 32(1):161-70. PubMed ID: 20171421
[TBL] [Abstract][Full Text] [Related]
16. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers.
Cánovas M; Torres F; Domenech G; Cebrecos J; Pelagio P; Martínez G; Polonio F; Cabré F
Arzneimittelforschung; 2011; 61(9):489-93. PubMed ID: 22029223
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method.
Zaid AN; Abualhasan MN; Watson DG; Mousa A; Ghazal N; Bustami R
Drug Des Devel Ther; 2015; 9():5315-21. PubMed ID: 26451086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
